Aptar Reports Third Quarter 2026 Results
Crystal Lake, Illinois, October 29, 2026 -- AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today reported the following third quarter results for the period ended September 30, 2026, as compared to the corresponding period of the last fiscal year.
Reported net income was $33 million and reported earnings per share were $0.51, impacted by deconsolidation of the Russian subsidiary
Adjusted earnings per share were $1.52, at the higher end of the guidance range, compared to $1.62 in the prior year period at comparable exchange rates
Returned $61 million in the quarter and $272 million year-to-date to shareholders through share repurchases and dividends
Subsequent to the quarter, the Board of Directors approved an increase in the quarterly cash dividend from $0.48 to $0.50 “We delivered broad-based revenue growth across all three segments. Pharma delivered impressive growth in central nervous system therapies, pulmonary, injectables and consumer healthcare, while maintaining profitability at the high end of our long-term target range. Our Pharma pipeline remains strong, with continued focus on building the pipeline and converting opportunities into future growth. New technologies and development programs are expanding the role we can play with customers across the drug development cycle. Beauty and Closures also delivered strong top-line growth, including double-digit core sales growth in Closures, where innovation in beverage dispensing continues to gain momentum. As I begin my tenure as CEO, our direction is clear: deepen our position with customers, accelerate innovation, execute with greater consistency and allocate capital thoughtfully. These priorities will guide how we drive profitable growth and create long-term value for Aptar and our shareholders,” said Gael Touya, Aptar President and CEO.
For the quarter ended September 30, 2026, reported sales increased 6% to $1.02 billion compared to $961 million in the prior year and core sales increased 5% compared to the prior year period.
Third Quarter Segment Sales Analysis(Change Over Prior Year) Pharma Beauty Closures Total AptarGroup Reported Sales Growth 2% 9% 11% 6% Currency Effects(1) 1% 0% (1)% 0% Acquisitions / (2)% (1)% 1% (1)% Deconsolidation Core Sales Growth 1% 8% 11% 5%
(1) - Currency effects are approximated by translating last year's amounts at this year's foreign exchange rates. 1 Pharma’s reported sales increased 2% compared to the prior year period and c ore sales increased 1%. Adjusting for emergency medicine destocking, Pharma delivered 8% core sales growth in the quarter. Performance was supported by continued growth across a number of end markets, including central nervous system and pulmonary therapies, nasal decongestants, eye care and dermal drug delivery solutions, and demand related to biologics, vaccines and GLP-1 therapies. These growth drivers were partially offset by the anticipated reduction in emergency medicine sales. Pharma delivered adjusted EBITDA margin of 36.4% a decline of 80 basis points, remaining above our long-term target despite a short-term unfavorable product mix related to destocking. Royalties and productivity improvements continued to positively impact margins.
Beauty’s reported sales increased 9% when compared to the prior year period, with core sales growth of 8%. There was increased demand for prestige fragrance dispensing, color cosmetics, as well as hair care applications, and pass throughs of higher input costs also contributed positively. Adjusted EBITDA margin was 11.4%, a decline of 70 basis points, including unfavorable mix and ongoing challenges in North American operations.
Closures’ reported sales rose 11% from the prior year period, with c ore sales growth of 11%. Beverage and food sales grew significantly, led by strong demand for bottled water and concentrates, continued momentum from our latest beverage dispensing closure innovation, as well as strong condiment sales. Pass throughs of higher input costs contributed positively to core sales growth, however, the dilutive impact drove the decline of 60 basis points in Adjusted EBITDA margin to 15.5%.
During the third quarter, Aptar deconsolidated its Russian subsidiary following a governmental decree placing the subsidiary under external administration and the resulting loss of control. Aptar recorded a $58.0 million loss on deconsolidation which included approximately $30.0 million of cash held by the subsidiary. The combined impact was $61.2 million before tax, including approximately $2.6 million of related receivable reserves and $0.5 million of related legal costs; and $60.4 million after tax, or $0.94 per diluted share.
Reported third quarter earnings per share were $0.51 compared to $1.92 reported a year ago. Adjusted earnings per share were $1.52, compared to the prior year period’s adjusted earnings per share of $1.62, including comparable exchange rates. The third quarter reported effective tax rate was 45.6%, reflecting the non-deductible tax impact of the deconsolidation of the Russian subsidiary. The adjusted effective tax rate was 23.4%, compared to the prior year period’s reported effective tax rate of 17.1% and adjusted effective tax rate of 20.8%.
For the nine months ended September 30, 2026, reported sales increased 8% to $3.03 billion compared to $2.81 billion in the prior year and core sales increased 2%.
Nine Months Year-To-Date Segment Sales Analysis(Change Over Prior Year) Pharma Beauty Closures Total AptarGroup Total Reported Sales 4% 12% 7% 8% Growth Currency Effects(1) (3)% (4)% (3)% (4)% Acquisitions / (1)% (4)% 1% (2)% Deconsolidation Core Sales Growth 0% 4% 5% 2%
(1) - Currency effects are approximated by translating last year's amounts at this year's foreign exchange rates. For the nine months ended September 30, 2026, Aptar’s reported earnings per share were $3.00, a decrease of 37%, which was also impacted by the deconsolidation of the Russian subsidiary, compared to $4.75 reported a year ag o. For the first nine months of 2026, adj usted earnings per share were $4.13 and decreased 10% from prior year adjusted earnings per share of $4.60, including comparable exchange rates. The current year had a reported effective tax rate of 28.1% and an adjusted effective tax rate of 23.2% compared to the prior year reported and adjusted effective tax rates of 20.4% and 21.9%, respectively. 2
Regarding Aptar’s outlook, Touya stated, “We expect Aptar to finish the year strong, supported by continued Pharma growth, particularly in consumer healthcare and injectables and without the headwind from emergency medicine destocking. Our Pharma pipeline remains strong, with new technologies and development programs expanding our reach across therapeutic areas and advancing opportunities for future growth. Closures continues its great momentum, with innovation helping drive increased demand, particularly for our beverage technologies. In Beauty, we remain focused on improving our long-term North American trajectory, while we continue to see pockets of healthy demand in areas, such as prestige fragrance, globally.”
Aptar currently expects adjusted earnings per share for the fourth quarter of 2026 to be in the range of $1.39 to $1.47. This guidance assumes an effective tax rate range of 17.5% to 19.5%. The earnings per share guidance range is assuming a 1.12 Euro to USD exchange rate.
During the third quarter, Aptar repurchased approximately 234 thousand shares for $30 million. Aptar may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions. As previously announced, Aptar’s Board of Directors approved a quarterly cash dividend of $0.50 per share. The payment date is December 3, 2026, to stockholders of record as of November 12, 2026.
There will be a conference call held on Friday, October 30, 2026 at 8:00 a.m. Central Time to discuss the company’s third quarter results for 2026. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investor Relations website at investors.aptar.com. Replay of the conference call can also be accessed for a limited time on the Investor Relations page of the website.
Aptar is a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing. Aptar partners with the world’s top healthcare and consumer brands to deliver medicines and create exceptional user experiences. Serving diverse markets, from pharmaceutical to beauty to food and beverage, Aptar combines market expertise with proprietary design, engineering and science to develop innovative solutions that help improve lives worldwide. Headquartered in Crystal Lake, Illinois, Aptar employs 14,000 dedicated people across 20 countries. Learn more at http://www.aptar.com. 3
This press release refers to certain non-GAAP financial measures, including current year adjusted earnings per share and adjusted EBITDA, which exclude the impact of restructuring initiatives, acquisition-related costs, certain purchase accounting adjustments related to acquisitions and investments, gains from remeasurement of equity method investments and net unrealized investment gains and losses related to observable market price changes on equity securities, Russia deconsolidation impacts, and other special items. Core sales and adjusted earnings per share also neutralize the impact of foreign currency translation effects when comparing current results to the prior year. Core sales also exclude material acquisitions and, for the three and nine months ended September 30, 2026, the Russian subsidiary’s net sales from both periods. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, purchase accounting adjustments related to acquisitions and investments, gains from remeasurement of equity method investments, net unrealized investment gains and losses related to observable market price changes on equity securities, Russia deconsolidation impacts, and other special items. Russia deconsolidation impacts comprise the loss on deconsolidation of our Russian subsidiary and related receivable reserves and legal costs described above, which we exclude because they resulted from a government action rather than from the operations of our businesses and therefore do not reflect the underlying performance of our remaining operations. For the three and nine months ended September 30, 2026 and 2025, “Other special items” include costs incurred related to non-ordinary-cour se litigation, specifically: lawsuits between Aptar and ARS Pharmaceuticals, Inc., involving Aptar’s claims of trade-secret misappropriation and contractual breaches and ARS’s lawsuit against Aptar under U.S. antitrust laws; and patent infringement actions filed by Nemera La Verpillière SAS in Germany and France relating to certain of Aptar’s ophthalmic products. These costs are excluded because they do not reflect our core operating performance. Please refer to “Legal Proceedings” within Note 13 - Commitments and Contingencies within Aptar’s Form 10-K for the year ended December 31, 2025 and subsequent SEC filings for more information. Adjusted EBITDA margin is adjusted EBITDA divided by reported net sales. Non- GAAP financial measures may not be comparable to similarly titled non-GAAP financial measures provided by other companies. Aptar’s management believes these non-GAAP financial measures provide useful information to our investors because they allow for a better period over period comparison of operating results by removing the impact of items that, in management’s view, do not reflect Aptar’s core operating performance. These non-GAAP financial measures also provide investors with certain information used by Aptar’s management when making financial and operational decisions. Free cash flow is calculated as cash provided by operating activities less capital expenditures plus proceeds from government grants related to capital expenditures. We use free cash flow to measure cash flow generated by operations that is available for dividends, share repurchases, acquisitions and debt repayment. We believe that it is meaningful to investors in evaluating our financial performance and measuring our ability to generate cash internally to fund our initiatives. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial results but should be read in conjunction with the unaudited condensed consolidated statements of income and other information presented herein. A reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures is included in the accompanying tables. Our outlook is provided on a non-GAAP basis because certain reconciling items are dependent on future events that either cannot be controlled, such as exchange rates and changes in the fair value of equity investments, or reliably predicted because they are not part of our routine activities, such as restructuring initiatives, acquisition- related costs and other special items. 4 This press release contains forward-looking statements, including certain statements set forth under the “Outlook” section of this press release. Words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential,” “continues” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: geopolitical conflicts worldwide and the resulting indirect impact on demand from our customers selling their products into these countries and certain supply chain disruptions; as well as governmental actions affecting our foreign operations and assets, including the loss of control over, and our ability to recover value from, our Russian operations; cybersecurity threats against our systems and/or service providers that could impact our networks and reporting systems; the availability of raw materials and components (particularly from sole sourced suppliers for some of our Pharma solutions) as well as the financial viability of these suppliers; our ability to protect and defend our intellectual property rights, as well as litigation involving intellectual property rights; the outcome of any legal proceeding that has been or may be instituted against us and others; our ability to keep pace with competition and technological advances, including in connection with the shifting of Pharma origination to less regulated markets; lower demand and asset utilization due to an economic recession either globally or in key markets we operate within; economic conditions worldwide, including inflationary conditions and potential deflationary conditions in other regions we rely on for growth; significant tariffs and other restrictions on foreign imports imposed by the U.S. and related countermeasures taken by impacted foreign countries; our ability to successfully implement facility expansions and new facility projects; fluctuations in the cost of materials, components, transportation cost as a result of supply chain disruptions and labor shortages, and other input costs; significant fluctuations in foreign currency exchange rates or our effective tax rate and cash flow; the impact of tax reform legislation, changes in tax rates and other tax-related events or transactions that could impact our effective tax rate; financial conditions of customers and suppliers; consolidations within our customer or supplier bases; changes in customer and/or consumer spending levels; loss of one or more key products or accounts; our ability to offset inflationary impacts with cost containment, productivity initiatives and price increases; changes in capital availability or cost, interest rate volatility; loss of royalty revenue due to contract expirations; volatility of global credit markets; our ability to identify potential new acquisitions and to successfully acquire and integrate such operations, including the successful integration of the businesses we have acquired; our ability to build out acquired businesses and integrate the product/service offerings of the acquired entities into our existing product/service portfolio; direct or indirect consequences of acts of war, terrorism or social unrest; the impact of natural disasters and other weather- related occurrences; fiscal and monetary policies and other regulations; changes, difficulties or failures in complying with government regulation, including FDA or similar foreign governmental authorities; changing regulations or market conditions regarding environmental sustainability; our ability to retain key members of management and manage labor costs; work stoppages due to labor disputes; our ability to meet future cash flow estimates to support our goodwill impairment testing; the demand for existing and new products; the success of our customers’ products, particularly in the pharmaceutical industry; our ability to manage worldwide customer launches of complex technical products, particularly in developing markets; difficulties in product development and uncertainties related to the timing or outcome of product development; significant product liability claims; and other risks associated with our operations. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K and Form 10-Qs. Readers are cautioned not to place undue reliance on forward-looking statements. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Nine Months Ended September 30, 2026 2025 ────────────────────────────────────────────────────────────────────────────── Cash Flows from Operating Activities: Net income $ 193,599 $ 318,227 Adjustments to reconcile net income to net cash provided by operations: Depreciation 198,044 177,412 Amortization 32,866 33,373 Stock-based compensation 33,043 36,772 Provision for CECL 4,374 516 Loss (gain) on disposition of fixed 484 77 assets Loss on Russia deconsolidation 58,020 — Net loss (gain) on remeasurement of 1,160 -845 equity securities Deferred income taxes -5,257 -31,851 Defined benefit plan expense 6,898 10,232 Equity in results of affiliates -3,224 -6,142 Gain on remeasurement of equity method — -26,518 investment Impairment loss 5,007 — Changes in balance sheet items, excluding effects from foreign currency adjustments:
Accounts and other receivables -101,728 -66,812 Inventories -56,698 -22,782 Prepaid and other current assets -17,906 -28,064 Accounts payable, accrued and other 60,132 6,950 liabilities Income taxes payable -5,250 -1,281 Retirement and deferred compensation -6,183 -5,891 plan liabilities Retirement and deferred compensation 420 -7,314 plan assets Other changes, net -8,023 247 Net Cash Provided by Operations 389,778 386,306 Cash Flows from Investing Activities: Capital expenditures -191,965 -183,600 Proceeds from government grants — 3,308 Proceeds from sale of property, plant 1,544 2,103 and equipment (Purchases) and maturities of short-term -1,462 2,813 investments Acquisition of business, net of cash -156 -28,221 acquired and release of escrow Acquisition of intangible assets, net -1,933 -4,301 Investment in equity securities — -7,258 Cash balance of deconsolidated -29,977 — subsidiary Notes receivable, net 1,355 37 Net Cash Used by Investing Activities -222,594 -215,119 Cash Flows from Financing Activities: Proceeds from notes payable and 20,826 2,105 overdrafts Repayments of notes payable and -21,281 -1,946 overdrafts Proceeds of short term revolving credit 50,000 144,620 facility, net Proceeds from long-term obligations 6,112 1,204 Repayments of long-term obligations -160,897 -36,490 Payment of contingent consideration -3,730 — obligation Dividends paid -92,054 -89,287 Proceeds from stock option exercises 22,420 14,869 Purchase of treasury stock -179,973 -190,005 Redeemable noncontrolling interest 1,106 703 Net Cash Used by Financing Activities -357,471 -154,227 Effect of Exchange Rate Changes on Cash -7,961 16,253 Net Decrease in Cash and Equivalents and -198,248 33,213 Restricted Cash Cash and Equivalents and Restricted Cash 404,849 223,844 at Beginning of Period Cash and Equivalents and Restricted Cash $ 206,601 $ 257,057 at End of Period
Three Nine Months Months Ended Ended September September 2026 30, 2025 2026 30, 2025 ────────────────────────────────────────────────────────────────────────────── Net Income Attribu… to $ 0.51 $ 1.92 $ 3.00 $ 4.75 AptarGr… Inc. Per Diluted Share Adjustm… Restruc… 0.02 0.02 0.05 0.06 initiat… Net investm… 0.01 — 0.01 -0.01 loss (gain) Realized gain on investm… included in — — — — net investm… loss (gain) above Russia 0.94 — 0.94 — deconso… Gain from remeasu… of — -0.40 — -0.40 equity method investm… Transac… costs related — 0.01 — 0.01 to acquisi… Purchase account… adjustm… related — 0.02 — 0.02 to acquisi… and investm… Other special 0.04 0.05 0.13 0.05 items Foreign currency — 0.12 effects (1) Adjusted Net Income Attribu… to $ 1.52 $ 1.62 $ 4.13 $ 4.60 AptarGr… Inc. Per Diluted Share
(1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using current period foreign currency exchange rates. 13
Three Months Ending December 31, Expected 2026 2025 ────────────────────────────────────────────────────────────────────────────── Income before Income Taxes $ 91,522 Adjustments: Restructuring initiatives 4,048 Curtailment gain related to -115 restructuring initiatives Net investment loss 1,328 Transaction costs related to 368 acquisitions Purchase accounting adjustments related 645 to acquisitions and investments Other special items 3,960 Foreign currency effects (1) -2,485 Adjusted Earnings before Income Taxes $ 99,271 Provision for Income Taxes $ 17,252 Adjustments: Restructuring initiatives 1,015 Curtailment gain related to -30 restructuring initiatives Net investment loss 325 Transaction costs related to 125 acquisitions Purchase accounting adjustments related 110 to acquisitions and investments Other special items 970 Foreign currency effects (1) -468 Adjusted Provision for Income Taxes $ 19,299 Net Loss Attributable to Noncontrolling $ 130 Interests Net Income Attributable to Redeemable $ -56 Noncontrolling Interests Net Income Attributable to AptarGroup, $ 74,344 Inc. Adjustments: Restructuring initiatives 3,033 Curtailment gain related to -85 restructuring initiatives Net investment loss 1,003 Transaction costs related to 243 acquisitions Purchase accounting adjustments related 535 to acquisitions and investments Other special items 2,990 Foreign currency effects (1) -2,017 Adjusted Net Income Attributable to $ 80,046 AptarGroup, Inc. Average Number of Diluted Shares 65,796 Outstanding
Three Months Ending December 31, Expected 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net Income Attributable to AptarGroup, $ 1.13 Inc. Per Diluted Share Adjustments: Restructuring initiatives 0.05 Curtailment gain related to — restructuring initiatives Net investment loss 0.01 Transaction costs related to — acquisitions Purchase accounting adjustments related 0.01 to acquisitions and investments Other special items 0.05 Foreign currency effects (1) -0.03 Adjusted Net Income Attributable to $1.39 - $1.47 $ 1.22 AptarGroup, Inc. Per Diluted Share (2)
(1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using current spot rates for all applicable foreign currency exchange rates.
(2) AptarGroup’s expected adjusted earnings per share range for the fourth quarter of 2026, see non-GAAP section for full definition, is based on an effective tax rate range of 17.5% to 19.5%. This tax rate range compares to our fourth quarter of 2025 effective tax rate of 18.9% on reported earnings per share and 19.4% on adjusted earnings per share. 16
Full text with the tables
Exhibit 99.1
Aptar Reports Third Quarter 2026 Results
Crystal Lake, Illinois, October 29, 2026 -- AptarGroup, Inc. (NYSE:ATR), a
global leader in drug delivery, dosing and protection technologies, and consumer
product dispensing, today reported the following third quarter results for the
period ended September 30, 2026, as compared to the corresponding period of the
last fiscal year.
Third Quarter 2026 Highlights
(Compared to the prior year quarter; see Non-GAAP section for full definitions;
see reconciliation for Non-GAAP measures)
•
Reported sales increased 6% and core sales increased 5%
•
Reported net income was $33 million and reported earnings per share were $0.51,
impacted by deconsolidation of the Russian subsidiary
•
Adjusted earnings per share were $1.52, at the higher end of the guidance range,
compared to $1.62 in the prior year period at comparable exchange rates
•
Adjusted EBITDA margin was 21.3%, compared to 23.2% in the prior year quarter
•
Returned $61 million in the quarter and $272 million year-to-date to
shareholders through share repurchases and dividends
•
Subsequent to the quarter, the Board of Directors approved an increase in the
quarterly cash dividend from $0.48 to $0.50
“We delivered broad-based revenue growth across all three segments. Pharma
delivered impressive growth in central nervous system therapies, pulmonary,
injectables and consumer healthcare, while maintaining profitability at the high
end of our long-term target range. Our Pharma pipeline remains strong, with
continued focus on building the pipeline and converting opportunities into
future growth. New technologies and development programs are expanding the role
we can play with customers across the drug development cycle. Beauty and
Closures also delivered strong top-line growth, including double-digit core
sales growth in Closures, where innovation in beverage dispensing continues to
gain momentum. As I begin my tenure as CEO, our direction is clear: deepen our
position with customers, accelerate innovation, execute with greater consistency
and allocate capital thoughtfully. These priorities will guide how we drive
profitable growth and create long-term value for Aptar and our shareholders,”
said Gael Touya, Aptar President and CEO.
Third Quarter Results
For the quarter ended September 30, 2026, reported sales increased 6% to $1.02
billion compared to $961 million in the prior year and core sales increased 5%
compared to the prior year period.
Third Quarter Segment
Sales
Analysis(Change Over
Prior Year)
Pharma Beauty Closures Total AptarGroup
Reported Sales Growth 2% 9% 11% 6%
Currency Effects(1) 1% 0% (1)% 0%
Acquisitions / (2)% (1)% 1% (1)%
Deconsolidation
Core Sales Growth 1% 8% 11% 5%
(1) - Currency effects are approximated by translating last year's amounts at
this year's foreign exchange rates.
1
Pharma’s reported sales increased 2% compared to the prior year period and c ore
sales increased 1%. Adjusting for emergency medicine destocking, Pharma
delivered 8% core sales growth in the quarter. Performance was supported by
continued growth across a number of end markets, including central nervous
system and pulmonary therapies, nasal decongestants, eye care and dermal drug
delivery solutions, and demand related to biologics, vaccines and GLP-1
therapies. These growth drivers were partially offset by the anticipated
reduction in emergency medicine sales. Pharma delivered adjusted EBITDA margin
of 36.4% a decline of 80 basis points, remaining above our long-term target
despite a short-term unfavorable product mix related to destocking. Royalties
and productivity improvements continued to positively impact margins.
Beauty’s reported sales increased 9% when compared to the prior year period,
with core sales growth of 8%. There was increased demand for prestige fragrance
dispensing, color cosmetics, as well as hair care applications, and pass
throughs of higher input costs also contributed positively. Adjusted EBITDA
margin was 11.4%, a decline of 70 basis points, including unfavorable mix and
ongoing challenges in North American operations.
Closures’ reported sales rose 11% from the prior year period, with c ore sales
growth of 11%. Beverage and food sales grew significantly, led by strong demand
for bottled water and concentrates, continued momentum from our latest beverage
dispensing closure innovation, as well as strong condiment sales. Pass throughs
of higher input costs contributed positively to core sales growth, however, the
dilutive impact drove the decline of 60 basis points in Adjusted EBITDA margin
to 15.5%.
During the third quarter, Aptar deconsolidated its Russian subsidiary following
a governmental decree placing the subsidiary under external administration and
the resulting loss of control. Aptar recorded a $58.0 million loss on
deconsolidation which included approximately $30.0 million of cash held by the
subsidiary. The combined impact was $61.2 million before tax, including
approximately $2.6 million of related receivable reserves and $0.5 million of
related legal costs; and $60.4 million after tax, or $0.94 per diluted share.
Reported third quarter earnings per share were $0.51 compared to $1.92 reported
a year ago. Adjusted earnings per share were $1.52, compared to the prior year
period’s adjusted earnings per share of $1.62, including comparable exchange
rates. The third quarter reported effective tax rate was 45.6%, reflecting the
non-deductible tax impact of the deconsolidation of the Russian subsidiary. The
adjusted effective tax rate was 23.4%, compared to the prior year period’s
reported effective tax rate of 17.1% and adjusted effective tax rate of 20.8%.
Nine Months Year-to-Date Results
For the nine months ended September 30, 2026, reported sales increased 8% to
$3.03 billion compared to $2.81 billion in the prior year and core sales
increased 2%.
Nine Months Year-To-Date
Segment Sales
Analysis(Change Over
Prior Year)
Pharma Beauty Closures Total AptarGroup
Total Reported Sales 4% 12% 7% 8%
Growth
Currency Effects(1) (3)% (4)% (3)% (4)%
Acquisitions / (1)% (4)% 1% (2)%
Deconsolidation
Core Sales Growth 0% 4% 5% 2%
(1) - Currency effects are approximated by translating last year's amounts at
this year's foreign exchange rates.
For the nine months ended September 30, 2026, Aptar’s reported earnings per
share were $3.00, a decrease of 37%, which was also impacted by the
deconsolidation of the Russian subsidiary, compared to $4.75 reported a year ag
o. For the first nine months of 2026, adj usted earnings per share were $4.13
and decreased 10% from prior year adjusted earnings per share of $4.60,
including comparable exchange rates. The current year had a reported effective
tax rate of 28.1% and an adjusted effective tax rate of 23.2% compared to the
prior year reported and adjusted effective tax rates of 20.4% and 21.9%,
respectively.
2
Outlook
Regarding Aptar’s outlook, Touya stated, “We expect Aptar to finish the year
strong, supported by continued Pharma growth, particularly in consumer
healthcare and injectables and without the headwind from emergency medicine
destocking. Our Pharma pipeline remains strong, with new technologies and
development programs expanding our reach across therapeutic areas and advancing
opportunities for future growth. Closures continues its great momentum, with
innovation helping drive increased demand, particularly for our beverage
technologies. In Beauty, we remain focused on improving our long-term North
American trajectory, while we continue to see pockets of healthy demand in
areas, such as prestige fragrance, globally.”
Aptar currently expects adjusted earnings per share for the fourth quarter of
2026 to be in the range of $1.39 to $1.47. This guidance assumes an effective
tax rate range of 17.5% to 19.5%. The earnings per share guidance range is
assuming a 1.12 Euro to USD exchange rate.
Cash Dividends and Share Repurchases
During the third quarter, Aptar repurchased approximately 234 thousand shares
for $30 million. Aptar may repurchase shares through the open market, privately
negotiated transactions or other programs, subject to market conditions. As
previously announced, Aptar’s Board of Directors approved a quarterly cash
dividend of $0.50 per share. The payment date is December 3, 2026, to
stockholders of record as of November 12, 2026.
Open Conference Call
There will be a conference call held on Friday, October 30, 2026 at 8:00 a.m.
Central Time to discuss the company’s third quarter results for 2026. The call
will last approximately one hour. Interested parties are invited to listen to a
live webcast by visiting the Investor Relations website at investors.aptar.com.
Replay of the conference call can also be accessed for a limited time on the
Investor Relations page of the website.
About Aptar
Aptar is a global leader in drug delivery, dosing and protection technologies,
and consumer product dispensing. Aptar partners with the world’s top healthcare
and consumer brands to deliver medicines and create exceptional user
experiences. Serving diverse markets, from pharmaceutical to beauty to food and
beverage, Aptar combines market expertise with proprietary design, engineering
and science to develop innovative solutions that help improve lives worldwide.
Headquartered in Crystal Lake, Illinois, Aptar employs 14,000 dedicated people
across 20 countries. Learn more at http://www.aptar.com.
3
Presentation of Non-GAAP Information
This press release refers to certain non-GAAP financial measures, including
current year adjusted earnings per share and adjusted EBITDA, which exclude the
impact of restructuring initiatives, acquisition-related costs, certain purchase
accounting adjustments related to acquisitions and investments, gains from
remeasurement of equity method investments and net unrealized investment gains
and losses related to observable market price changes on equity securities,
Russia deconsolidation impacts, and other special items. Core sales and adjusted
earnings per share also neutralize the impact of foreign currency translation
effects when comparing current results to the prior year. Core sales also
exclude material acquisitions and, for the three and nine months ended September
30, 2026, the Russian subsidiary’s net sales from both periods. Adjusted EBITDA
is defined as earnings before net interest, taxes, depreciation, amortization,
restructuring initiatives, acquisition-related costs, purchase accounting
adjustments related to acquisitions and investments, gains from remeasurement of
equity method investments, net unrealized investment gains and losses related to
observable market price changes on equity securities, Russia deconsolidation
impacts, and other special items. Russia deconsolidation impacts comprise the
loss on deconsolidation of our Russian subsidiary and related receivable
reserves and legal costs described above, which we exclude because they resulted
from a government action rather than from the operations of our businesses and
therefore do not reflect the underlying performance of our remaining operations.
For the three and nine months ended September 30, 2026 and 2025, “Other special
items” include costs incurred related to non-ordinary-cour se litigation,
specifically: lawsuits between Aptar and ARS Pharmaceuticals, Inc., involving
Aptar’s claims of trade-secret misappropriation and contractual breaches and
ARS’s lawsuit against Aptar under U.S. antitrust laws; and patent infringement
actions filed by Nemera La Verpillière SAS in Germany and France relating to
certain of Aptar’s ophthalmic products. These costs are excluded because they do
not reflect our core operating performance. Please refer to “Legal Proceedings”
within Note 13 - Commitments and Contingencies within Aptar’s Form 10-K for the
year ended December 31, 2025 and subsequent SEC filings for more information.
Adjusted EBITDA margin is adjusted EBITDA divided by reported net sales. Non-
GAAP financial measures may not be comparable to similarly titled non-GAAP
financial measures provided by other companies. Aptar’s management believes
these non-GAAP financial measures provide useful information to our investors
because they allow for a better period over period comparison of operating
results by removing the impact of items that, in management’s view, do not
reflect Aptar’s core operating performance. These non-GAAP financial measures
also provide investors with certain information used by Aptar’s management when
making financial and operational decisions. Free cash flow is calculated as cash
provided by operating activities less capital expenditures plus proceeds from
government grants related to capital expenditures. We use free cash flow to
measure cash flow generated by operations that is available for dividends, share
repurchases, acquisitions and debt repayment. We believe that it is meaningful
to investors in evaluating our financial performance and measuring our ability
to generate cash internally to fund our initiatives. These non-GAAP financial
measures should not be considered in isolation or as a substitute for GAAP
financial results but should be read in conjunction with the unaudited condensed
consolidated statements of income and other information presented herein. A
reconciliation of non-GAAP financial measures to the most directly comparable
GAAP measures is included in the accompanying tables. Our outlook is provided on
a non-GAAP basis because certain reconciling items are dependent on future
events that either cannot be controlled, such as exchange rates and changes in
the fair value of equity investments, or reliably predicted because they are not
part of our routine activities, such as restructuring initiatives, acquisition-
related costs and other special items.
4
This press release contains forward-looking statements, including certain
statements set forth under the “Outlook” section of this press release. Words
such as “expects,” “anticipates,” “believes,” “estimates,” “future,”
“potential,” “continues” and other similar expressions or future or conditional
verbs such as “will,” “should,” “would” and “could” are intended to identify
such forward-looking statements. Forward-looking statements are made pursuant to
the safe harbor provisions of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs
as well as assumptions made by and information currently available to us.
Accordingly, our actual results or other events may differ materially from those
expressed or implied in such forward-looking statements due to known or unknown
risks and uncertainties that exist in our operations and business environment
including, but not limited to: geopolitical conflicts worldwide and the
resulting indirect impact on demand from our customers selling their products
into these countries and certain supply chain disruptions; as well as
governmental actions affecting our foreign operations and assets, including the
loss of control over, and our ability to recover value from, our Russian
operations; cybersecurity threats against our systems and/or service providers
that could impact our networks and reporting systems; the availability of raw
materials and components (particularly from sole sourced suppliers for some of
our Pharma solutions) as well as the financial viability of these suppliers; our
ability to protect and defend our intellectual property rights, as well as
litigation involving intellectual property rights; the outcome of any legal
proceeding that has been or may be instituted against us and others; our ability
to keep pace with competition and technological advances, including in
connection with the shifting of Pharma origination to less regulated markets;
lower demand and asset utilization due to an economic recession either globally
or in key markets we operate within; economic conditions worldwide, including
inflationary conditions and potential deflationary conditions in other regions
we rely on for growth; significant tariffs and other restrictions on foreign
imports imposed by the U.S. and related countermeasures taken by impacted
foreign countries; our ability to successfully implement facility expansions and
new facility projects; fluctuations in the cost of materials, components,
transportation cost as a result of supply chain disruptions and labor shortages,
and other input costs; significant fluctuations in foreign currency exchange
rates or our effective tax rate and cash flow; the impact of tax reform
legislation, changes in tax rates and other tax-related events or transactions
that could impact our effective tax rate; financial conditions of customers and
suppliers; consolidations within our customer or supplier bases; changes in
customer and/or consumer spending levels; loss of one or more key products or
accounts; our ability to offset inflationary impacts with cost containment,
productivity initiatives and price increases; changes in capital availability or
cost, interest rate volatility; loss of royalty revenue due to contract
expirations; volatility of global credit markets; our ability to identify
potential new acquisitions and to successfully acquire and integrate such
operations, including the successful integration of the businesses we have
acquired; our ability to build out acquired businesses and integrate the
product/service offerings of the acquired entities into our existing
product/service portfolio; direct or indirect consequences of acts of war,
terrorism or social unrest; the impact of natural disasters and other weather-
related occurrences; fiscal and monetary policies and other regulations;
changes, difficulties or failures in complying with government regulation,
including FDA or similar foreign governmental authorities; changing regulations
or market conditions regarding environmental sustainability; our ability to
retain key members of management and manage labor costs; work stoppages due to
labor disputes; our ability to meet future cash flow estimates to support our
goodwill impairment testing; the demand for existing and new products; the
success of our customers’ products, particularly in the pharmaceutical industry;
our ability to manage worldwide customer launches of complex technical products,
particularly in developing markets; difficulties in product development and
uncertainties related to the timing or outcome of product development;
significant product liability claims; and other risks associated with our
operations. For additional information on these and other risks and
uncertainties, please see our filings with the Securities and Exchange
Commission, including the discussion under “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” in our
Form 10-K and Form 10-Qs. Readers are cautioned not to place undue reliance on
forward-looking statements. We undertake no obligation to update publicly any
forward-looking statements, whether as a result of new information, future
events or otherwise, except as required by law.
Contacts
Investor Relations Contact
:
Mary Skafidas
[email protected]
815-479-5530
Media Contact:
Katie Reardon
[email protected]
815-479-5671
5
AptarGroup, Inc.
Condensed Consolidated Financial Statements (Unaudited)
(In Thousands, Except Per Share Data)
Consolidated Statements of Income
Three Nine
Months Months
Ended Ended
Septemb… Septem…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Net $ 1,019,1… $ 961,131 $ 3,028,… $ 2,814,4…
Sales
Cost
of
Sales
(excl…
of 646,196 598,046 1,938,… 1,747,9…
depre…
and
amort…
shown
below)
Selli…
Resea…
& 160,164 148,760 485,501 455,176
Devel…
and
Admin…
Depre…
and 75,544 75,234 230,910 210,785
Amort…
Restr… 2,208 2,168 4,713 5,789
Initi…
Opera… 135,007 136,923 369,225 394,764
Income
Other
Income
(Expe…
Inter… -15,790 -13,532 -48,733 -35,733
Expen…
Inter… 1,930 2,400 8,359 7,094
Income
Net
Inves… -1,011 -161 -1,160 845
(Loss)
Gain
Loss
on -58,020 — -58,020 —
Russia
Decon…
Equity
in
Resul… 1,106 1,747 3,224 6,142
of
Affil…
Gain
from
Remea…
of — 26,518 — 26,518
Equity
Method
Inves…
Misce…
Expen… -2,889 232 -3,744 226
net
Income
before 60,333 154,127 269,151 399,856
Income
Taxes
Provi…
for 27,511 26,295 75,552 81,629
Income
Taxes
Net $ 32,822 $ 127,832 $ 193,599 $ 318,227
Income
Net
(Inco…
Loss
Attri… -226 -47 -382 76
to
Nonco…
Inter…
Net
Loss
(Inco…
Attri… 6 142 -368 142
to
Redee…
Nonco…
Inter…
Net
Income
Attri… $ 32,602 $ 127,927 $ 192,849 $ 318,445
to
Aptar…
Inc.
Net
Income
Attri…
to
Aptar…
Inc.
per
Common
Share:
Basic $ 0.51 $ 1.95 $ 3.03 $ 4.83
Dilut… $ 0.51 $ 1.92 $ 3.00 $ 4.75
Avera…
Numbe…
of
Shares
Outst…
Basic 63,523 65,709 63,733 65,989
Dilut… 64,147 66,630 64,373 67,043
6
AptarGroup, Inc.
Condensed Consolidated Financial Statements (Unaudited)
(continued)
($ In Thousands)
Consolidated Balance Sheets
September 30, 2026 December 31, 2025
──────────────────────────────────────────────────────────────────────────────
ASSETS
Cash and Equivalents $ 204,176 $ 402,424
Short-term Investments 8,121 7,109
Accounts and Notes 883,939 803,830
Receivable, Net
Inventories 582,605 537,845
Prepaid and Other 157,950 142,354
Total Current Assets 1,836,791 1,893,562
Property, Plant and 1,635,530 1,676,479
Equipment, Net
Goodwill 1,067,152 1,077,898
Other Assets 572,153 604,780
Total Assets $ 5,111,626 $ 5,252,719
LIABILITIES, MEZZANINE
EQUITY AND
STOCKHOLDERS’ EQUITY
Short-Term Obligations $ 350,681 $ 343,531
Accounts Payable, Accrued
and Other 872,133 822,913
Liabilities
Total Current Liabilities 1,222,814 1,166,444
Long-Term Obligations 1,024,735 1,139,433
Deferred Liabilities and 202,894 234,617
Other
Total Liabilities 2,450,443 2,540,494
Redeemable Noncontrolling 28,048 26,244
Interests
Total Mezzanine Equity 28,048 26,244
AptarGroup, Inc. 2,614,324 2,668,096
Stockholders' Equity
Noncontrolling Interests in 18,811 17,885
Subsidiaries
Total Stockholders' Equity 2,633,135 2,685,981
Total Liabilities,
Mezzanine Equity and $ 5,111,626 $ 5,252,719
Stockholders' Equity
7
AptarGroup, Inc.
Condensed Consolidated Financial Statements (Unaudited)
(continued)
($ In Thousands)
Consolidated Statement of Cash Flows
Nine Months Ended September 30, 2026 2025
──────────────────────────────────────────────────────────────────────────────
Cash Flows from Operating Activities:
Net income $ 193,599 $ 318,227
Adjustments to reconcile net income to
net cash provided by operations:
Depreciation 198,044 177,412
Amortization 32,866 33,373
Stock-based compensation 33,043 36,772
Provision for CECL 4,374 516
Loss (gain) on disposition of fixed 484 77
assets
Loss on Russia deconsolidation 58,020 —
Net loss (gain) on remeasurement of 1,160 -845
equity securities
Deferred income taxes -5,257 -31,851
Defined benefit plan expense 6,898 10,232
Equity in results of affiliates -3,224 -6,142
Gain on remeasurement of equity method — -26,518
investment
Impairment loss 5,007 —
Changes in balance sheet items,
excluding effects from foreign currency
adjustments:
Accounts and other receivables -101,728 -66,812
Inventories -56,698 -22,782
Prepaid and other current assets -17,906 -28,064
Accounts payable, accrued and other 60,132 6,950
liabilities
Income taxes payable -5,250 -1,281
Retirement and deferred compensation -6,183 -5,891
plan liabilities
Retirement and deferred compensation 420 -7,314
plan assets
Other changes, net -8,023 247
Net Cash Provided by Operations 389,778 386,306
Cash Flows from Investing Activities:
Capital expenditures -191,965 -183,600
Proceeds from government grants — 3,308
Proceeds from sale of property, plant 1,544 2,103
and equipment
(Purchases) and maturities of short-term -1,462 2,813
investments
Acquisition of business, net of cash -156 -28,221
acquired and release of escrow
Acquisition of intangible assets, net -1,933 -4,301
Investment in equity securities — -7,258
Cash balance of deconsolidated -29,977 —
subsidiary
Notes receivable, net 1,355 37
Net Cash Used by Investing Activities -222,594 -215,119
Cash Flows from Financing Activities:
Proceeds from notes payable and 20,826 2,105
overdrafts
Repayments of notes payable and -21,281 -1,946
overdrafts
Proceeds of short term revolving credit 50,000 144,620
facility, net
Proceeds from long-term obligations 6,112 1,204
Repayments of long-term obligations -160,897 -36,490
Payment of contingent consideration -3,730 —
obligation
Dividends paid -92,054 -89,287
Proceeds from stock option exercises 22,420 14,869
Purchase of treasury stock -179,973 -190,005
Redeemable noncontrolling interest 1,106 703
Net Cash Used by Financing Activities -357,471 -154,227
Effect of Exchange Rate Changes on Cash -7,961 16,253
Net Decrease in Cash and Equivalents and -198,248 33,213
Restricted Cash
Cash and Equivalents and Restricted Cash 404,849 223,844
at Beginning of Period
Cash and Equivalents and Restricted Cash $ 206,601 $ 257,057
at End of Period
8
AptarGroup, Inc.
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)
($ In Thousands)
T…
M…
E…
S…
3…
2…
──────────────────────────────────────────────────────────────────────────────
C… N…
C… P… B… C… & I…
O…
… $ 1… $ 4… $ 3… $ 20… $ — $ —
…
…
… $ 3…
…
…
… 2…
…
…
…
… 6… 1… 5… -2… -3… -1…
…
…
…
… 2… 4… 1… -25 —
…
…
… 1… — — — 1,…
…
…
… 6… 3… 9… 40… 7,…
…
…
… 3… 3… — — —
…
…
…
… 1… 1… 1… 17… -2… -1…
…
…
… 1… 15…
…
… -… -1…
…
…
…
…
…
… 1… 1… 1… 17… -2… —
…
…
…
…
…
… 7… 3… 2… 14… 1,…
…
…
…
…
…
…
… $ 2… $ 1… $ 4… $ 32… $ -2… $ —
…
…
…
…
…
…
…
…
…
…
… 3… %
…
/
…
…
…
…
…
…
…
… 2… % 3… % 1… % 15… %
/
…
…
…
T…
M…
E…
S…
3…
2…
──────────────────────────────────────────────────────────────────────────────
C… N…
C… P… B… C… & I…
O…
… $ 9… $ 4… $ 3… $ 18… $ — $ —
…
…
… $ 1…
…
…
… 2…
…
…
…
… 1… 1… 4… 14… -1… -1…
…
…
…
… 2… 9… 5… 702 -3
…
…
… 1… — — — 161
…
…
…
…
… -… — -… — —
…
…
…
…
…
… 7… 5… 1… — —
…
…
…
…
…
… 1… — 1… — —
…
…
…
…
…
… 4… 4… — — —
…
…
…
… 1… 1… 1… 15… -1… -1…
…
…
… 1… 13…
…
… -… -2…
…
…
…
…
…
… 1… 1… 1… 15… -1… —
…
…
…
…
…
… 7… 3… 2… 14… 874
…
…
…
…
…
…
… $ 2… $ 1… $ 3… $ 30… $ -1… $ —
…
…
…
…
…
…
…
…
…
…
… 1… %
…
/
…
…
…
…
…
…
…
… 2… % 3… % 1… % 16… %
/
…
…
…
9
AptarGroup, Inc.
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)
($ In Thousands)
N…
M…
E…
S…
3…
2…
──────────────────────────────────────────────────────────────────────────────
C… N…
C… P… B… C… & I…
O…
… $ 3… $ 1… $ 1… $ 58… $ — $ —
…
…
… $ 1…
…
…
… 7…
…
…
…
… 2… 3… 3… 1,… -7… -4…
…
…
…
… 4… 3… 4… 311 -4…
…
…
… 1… — — — 1,…
…
…
…
…
…
… 88 — — — 88
…
…
…
…
…
…
… 6… 3… 9… 40… 7,…
…
…
…
… 83 83 — — —
…
…
…
…
…
… 1… 1… — — —
…
…
…
…
…
… 1… 1… — — —
…
…
…
… 3… 3… 5… 42… -6… -4…
…
…
… 4… 48…
…
… -… -8…
…
…
…
…
…
… 3… 3… 5… 42… -6… —
…
…
…
…
…
… 2… 1… 7… 43… 3,…
…
…
…
…
…
…
… $ 6… $ 4… $ 1… $ 85… $ -5… $ —
…
…
…
…
…
…
…
…
…
…
… 6… %
…
/
…
…
…
…
…
…
…
… 2… % 3… % 1… % 14… %
/
…
…
…
10
AptarGroup, Inc.
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)
($ In Thousands)
N…
M…
E…
S…
3…
2…
──────────────────────────────────────────────────────────────────────────────
C… N…
C… P… B… C… & I…
O…
… $ 2… $ 1… $ 9… $ 54… $ — $ —
…
…
… $ 3…
…
…
… 8…
…
…
…
… 3… 3… 8… 44… -5… -2…
…
…
…
… 5… 1… 1… 2,… 97
…
…
… -… — — — -8…
…
…
…
…
… -… — -… — —
…
…
…
…
…
… 1… 5… 5… — —
…
…
…
…
…
… 1… — 1… — —
…
…
…
…
…
… 4… 4… — — —
…
…
…
… 3… 3… 5… 47… -5… -2…
…
…
… 3… 35…
…
… -… -7…
…
…
…
…
…
… 4… 3… 5… 47… -5… —
…
…
…
…
…
… 2… 1… 6… 41… 2,… —
…
…
…
…
…
…
… $ 6… $ 4… $ 1… $ 89… $ -5… $ —
…
…
…
…
…
…
…
…
…
…
… 1… %
…
/
…
…
…
…
…
…
…
… 2… % 3… % 1… % 16… %
/
…
…
…
11
AptarGroup, Inc.
Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited)
(In Thousands, Except Per Share Data)
Three Nine
Months Months
Ended Ended
Septem… Septemb…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Income
before $ 60,333 $ 154,127 $ 269,151 $ 399,856
Income
Taxes
Adjust…
Restru… 2,208 2,168 4,713 5,789
initia…
Net
invest… 1,011 161 1,160 -845
loss
(gain)
Realiz…
gain on
invest…
includ…
in — — 88 —
net
invest…
loss
(gain)
above
Russia
decons… 61,161 — 61,161 —
impact
Gain
from
remeas…
of — -26,518 — -26,518
equity
method
invest…
Transa…
costs
related — 748 83 1,092
to
acquis…
Purcha…
accoun…
adjust…
related — 1,148 145 1,148
to
acquis…
and
invest…
Other
special 3,095 4,400 10,899 4,400
items
Foreign
curren… -371 9,866
effects
(1)
Adjust…
Earnin…
before $ 127,808 $ 135,863 $ 347,400 $ 394,788
Income
Taxes
Provis…
for $ 27,511 $ 26,295 $ 75,552 $ 81,629
Income
Taxes
Adjust…
Restru… 557 561 1,240 1,488
initia…
Net
invest… 247 39 284 -207
loss
(gain)
Realiz…
gain on
invest…
includ…
in — — 22 —
net
invest…
loss
(gain)
above
Russia
decons… 785 — 785 —
impact
Gain
from
remeas…
of — — — —
equity
method
invest…
Transa…
costs
related — 182 20 268
to
acquis…
Purcha…
accoun…
adjust…
related — 172 49 172
to
acquis…
and
invest…
Other
special 788 1,078 2,815 1,078
items
Foreign
curren… -63 2,014
effects
(1)
Adjust…
Provis…
for $ 29,888 $ 28,264 $ 80,767 $ 86,442
Income
Taxes
Net
(Incom…
Loss
Attrib… $ -226 $ -47 $ -382 $ 76
to
Noncon…
Intere…
Net
(Incom…
Loss
Attrib… $ 6 $ 142 $ -368 $ 142
to
Redeem…
Noncon…
Intere…
Net
Income
Attrib… $ 32,602 $ 127,927 $ 192,849 $ 318,445
to
AptarG…
Inc.
Adjust…
Restru… 1,651 1,607 3,473 4,301
initia…
Net
invest… 764 122 876 -638
loss
(gain)
Realiz…
gain on
invest…
includ…
in — — 66 —
net
invest…
loss
(gain)
above
Russia 60,376 — 60,376 —
decons…
Gain
from
remeas…
of — -26,518 — -26,518
equity
method
invest…
Transa…
costs
related — 566 63 824
to
acquis…
Purcha…
accoun…
adjust…
related — 976 96 976
to
acquis…
and
invest…
Other
special 2,307 3,322 8,084 3,322
items
Foreign
curren… -308 7,852
effects
(1)
Adjust…
Net
Income
Attrib… $ 97,700 $ 107,694 $ 265,883 $ 308,564
to
AptarG…
Inc.
Average
Number
of 64,147 66,630 64,373 67,043
Diluted
Shares
Outsta…
12
Three Nine
Months Months
Ended Ended
September September
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Net
Income
Attribu…
to $ 0.51 $ 1.92 $ 3.00 $ 4.75
AptarGr…
Inc. Per
Diluted
Share
Adjustm…
Restruc… 0.02 0.02 0.05 0.06
initiat…
Net
investm… 0.01 — 0.01 -0.01
loss
(gain)
Realized
gain on
investm…
included
in — — — —
net
investm…
loss
(gain)
above
Russia 0.94 — 0.94 —
deconso…
Gain
from
remeasu…
of — -0.40 — -0.40
equity
method
investm…
Transac…
costs
related — 0.01 — 0.01
to
acquisi…
Purchase
account…
adjustm…
related — 0.02 — 0.02
to
acquisi…
and
investm…
Other
special 0.04 0.05 0.13 0.05
items
Foreign
currency — 0.12
effects
(1)
Adjusted
Net
Income
Attribu…
to $ 1.52 $ 1.62 $ 4.13 $ 4.60
AptarGr…
Inc. Per
Diluted
Share
(1) Foreign currency effects are approximations of the adjustment necessary to
state the prior year earnings and earnings per share using current period
foreign currency exchange rates.
13
AptarGroup, Inc.
Reconciliation of Free Cash Flow to Net Cash Provided by Operations (Unaudited)
(In Thousands)
Three Nine
Months Months
Ended Ended
Septem… Septemb…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Net
Cash
Provid… $ 167,598 $ 177,606 $ 389,778 $ 386,306
by
Operat…
Capital -69,006 -63,313 -191,965 -183,6…
Expend…
Procee…
from — — — 3,308
Govern…
Grants
Free
Cash $ 98,592 $ 114,293 $ 197,813 $ 206,014
Flow
14
AptarGroup, Inc.
Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited)
(In Thousands, Except Per Share Data)
Three Months Ending
December 31,
Expected 2026 2025
──────────────────────────────────────────────────────────────────────────────
Income before Income Taxes $ 91,522
Adjustments:
Restructuring initiatives 4,048
Curtailment gain related to -115
restructuring initiatives
Net investment loss 1,328
Transaction costs related to 368
acquisitions
Purchase accounting adjustments
related 645
to acquisitions and investments
Other special items 3,960
Foreign currency effects (1) -2,485
Adjusted Earnings before Income Taxes $ 99,271
Provision for Income Taxes $ 17,252
Adjustments:
Restructuring initiatives 1,015
Curtailment gain related to -30
restructuring initiatives
Net investment loss 325
Transaction costs related to 125
acquisitions
Purchase accounting adjustments
related 110
to acquisitions and investments
Other special items 970
Foreign currency effects (1) -468
Adjusted Provision for Income Taxes $ 19,299
Net Loss Attributable to
Noncontrolling $ 130
Interests
Net Income Attributable to Redeemable $ -56
Noncontrolling Interests
Net Income Attributable to
AptarGroup, $ 74,344
Inc.
Adjustments:
Restructuring initiatives 3,033
Curtailment gain related to -85
restructuring initiatives
Net investment loss 1,003
Transaction costs related to 243
acquisitions
Purchase accounting adjustments
related 535
to acquisitions and investments
Other special items 2,990
Foreign currency effects (1) -2,017
Adjusted Net Income Attributable to $ 80,046
AptarGroup, Inc.
Average Number of Diluted Shares 65,796
Outstanding
15
Three Months Ending
December 31,
Expected 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net Income Attributable to AptarGroup, $ 1.13
Inc. Per Diluted Share
Adjustments:
Restructuring initiatives 0.05
Curtailment gain related to —
restructuring initiatives
Net investment loss 0.01
Transaction costs related to —
acquisitions
Purchase accounting adjustments
related 0.01
to acquisitions and investments
Other special items 0.05
Foreign currency effects (1) -0.03
Adjusted Net Income Attributable to $1.39 - $1.47 $ 1.22
AptarGroup, Inc. Per Diluted Share (2)
(1) Foreign currency effects are approximations of the adjustment necessary to
state the prior year earnings and earnings per share using current spot rates
for all applicable foreign currency exchange rates.
(2) AptarGroup’s expected adjusted earnings per share range for the fourth
quarter of 2026, see non-GAAP section for full definition, is based on an
effective tax rate range of 17.5% to 19.5%. This tax rate range compares to our
fourth quarter of 2025 effective tax rate of 18.9% on reported earnings per
share and 19.4% on adjusted earnings per share.
16